Literature DB >> 19424632

Increased BTB-Kelch type substrate adaptor protein immunoreactivity associates with advanced stage and poor differentiation in renal cell carcinoma.

Hanna Ronkainen1, Markku H Vaarala, Saila Kauppila, Ylermi Soini, Timo K Paavonen, Jenni Rask, Pasi Hirvikoski.   

Abstract

Renal cell carcinoma (RCC) is a malignancy with increasing incidence. Despite the well-known prognostic factors - the stage, grade and histological subtype - the clinical course of RCC can seem quite random. The aim of this study was to evaluate markers of the oxidative system as candidate prognostic factors for RCC. Our study population consisted of 152 patients who underwent operation for RCC between 1990 and 1999. The tumours were examined with three immunohistochemical markers of the oxidative system, thioredoxin (Trx), NF-E2-related factor (Nfr2) and BTB-Kelch type substrate adaptor protein (Keap1). Cytoplasmic Keap1 staining was related to poorer prognosis in renal cancer-specific survival. The difference was statistically significant (P=0.02). Keap1 staining was associated with a more advanced stage and a higher nuclear grade. Cytoplasmic Trx staining was associated with a trend of better prognosis in renal cancer-specific survival. Nfr2 staining was not a prognostic factor in renal cancer-specific survival. In RCC, Keap1 is associated with a more advanced disease, a higher grade and a poorer prognosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19424632     DOI: 10.3892/or_00000383

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  7 in total

1.  Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features.

Authors:  Luisa M Solis; Carmen Behrens; Wenli Dong; Milind Suraokar; Natalie C Ozburn; Cesar A Moran; Alejandro H Corvalan; Shyam Biswal; Stephen G Swisher; B Nebiyou Bekele; John D Minna; David J Stewart; Ignacio I Wistuba
Journal:  Clin Cancer Res       Date:  2010-06-09       Impact factor: 12.531

2.  Dose-dependent proteomic analysis of glioblastoma cancer stem cells upon treatment with γ-secretase inhibitor.

Authors:  Lan Dai; Jintang He; Yashu Liu; Jaeman Byun; Anuradha Vivekanandan; Subramaniam Pennathur; Xing Fan; David M Lubman
Journal:  Proteomics       Date:  2011-10-24       Impact factor: 3.984

3.  Aberrant Keap1 methylation in breast cancer and association with clinicopathological features.

Authors:  Raffaela Barbano; Lucia Anna Muscarella; Barbara Pasculli; Vanna Maria Valori; Andrea Fontana; Michelina Coco; Annamaria la Torre; Teresa Balsamo; Maria Luana Poeta; Giovanni Francesco Marangi; Evaristo Maiello; Marina Castelvetere; Fabio Pellegrini; Roberto Murgo; Vito Michele Fazio; Paola Parrella
Journal:  Epigenetics       Date:  2012-12-18       Impact factor: 4.528

4.  Evaluation of myosin VI, E-cadherin and beta-catenin immunostaining in renal cell carcinoma.

Authors:  Hanna Ronkainen; Saila Kauppila; Pasi Hirvikoski; Markku H Vaarala
Journal:  J Exp Clin Cancer Res       Date:  2010-01-14

5.  Absent Toll-like receptor-9 expression predicts poor prognosis in renal cell carcinoma.

Authors:  Hanna Ronkainen; Pasi Hirvikoski; Saila Kauppila; Katri S Vuopala; Timo K Paavonen; Katri S Selander; Markku H Vaarala
Journal:  J Exp Clin Cancer Res       Date:  2011-09-19

6.  Clinical significance of Keap1 and Nrf2 in oral squamous cell carcinoma.

Authors:  Cong-Fa Huang; Lu Zhang; Si-Rui Ma; Zhi-Li Zhao; Wei-Ming Wang; Ke-Fei He; Yi-Fang Zhao; Wen-Feng Zhang; Bing Liu; Zhi-Jun Sun
Journal:  PLoS One       Date:  2013-12-27       Impact factor: 3.240

7.  Overexpression of NRF2 is correlated with prognoses of patients with malignancies: A meta-analysis.

Authors:  Yangyang Guo; Luyan Shen
Journal:  Thorac Cancer       Date:  2017-08-02       Impact factor: 3.500

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.